Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Interest & Investment Income: 2023-2024

Historic Interest & Investment Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $8.9 million.

  • Contineum Therapeutics' Interest & Investment Income rose 41.23% to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.9 million, marking a year-over-year increase of 93.36%. This contributed to the annual value of $8.9 million for FY2024, which is 93.33% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Interest & Investment Income of $8.9 million as of FY2024, which was up 93.33% from $4.6 million recorded in FY2023.
  • Over the past 5 years, Contineum Therapeutics' Interest & Investment Income peaked at $8.9 million during FY2024, and registered a low of $4.6 million during FY2023.
  • In the last 2 years, Contineum Therapeutics' Interest & Investment Income had a median value of $6.8 million in 2023 and averaged $6.8 million.
  • Data for Contineum Therapeutics' Interest & Investment Income shows a peak YoY surged of 93.33% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Interest & Investment Income (Yearly) stood at $4.6 million in 2023, then skyrocketed by 93.33% to $8.9 million in 2024.